Photo courtesy of LifeSemantics

Korean digital health company LifeSemantics has obtained the first approval for an AI-powered solution for skin cancer diagnosis in South Korea.

韩国数字健康公司LifeSemantics首次获得韩国皮肤癌诊断人工智能解决方案的批准。

The company received regulatory clearance from the Ministry of Food and Drug Safety for canofyMD SCAI four months after its application.

该公司在申请四个月后获得了食品和药物安全部对canofyMD SCAI的监管许可。

The mobile AI technology was developed through the Doctor Answer 2.0 project, which has gathered 30 hospitals and 19 technology companies to advance their medical AI development.

。

WHAT IT'S ABOUT

它是关于什么的

The flagship canofyMD solution uses convolutional neural network, an AI method for image recognition and processing, to detect and assist with the diagnosis of skin cancer in images taken from smartphones. It can identify malignant melanoma, basal cell carcinoma, and squamous cell carcinoma, as well as benign tumours. .

旗舰canofyMD解决方案使用卷积神经网络（一种用于图像识别和处理的人工智能方法）来检测和辅助智能手机图像中的皮肤癌诊断。。。

In March, LifeSemantics completed the clinical trial of the mobile screening app, the first such trial for skin cancer AI in South Korea. The AI, which was trained using 6,500 images of skin lesions collected from three local hospitals, was trialled in 199 cases. It later showed 'superior' results, including a diagnostic accuracy of 80.9%..

3月，LifeSemantics完成了移动筛查应用程序的临床试验，这是韩国第一个针对皮肤癌AI的此类试验。AI使用从三家当地医院收集的6500张皮肤病变图像进行了训练，并在199例病例中进行了试验。它后来显示出“优越”的结果，包括诊断准确率为80.9%。。

Following its regulatory clearance, LifeSemantics reportedly plans to further verify canofyMD SCAI in trials with six local hospitals.  It previously disclosed that it targets to commercially launch the app by the last quarter of the year. It also looks to file for regulatory approvals in Australia and New Zealand, where skin cancer rates are one of the highest worldwide. .

据报道，LifeSemantics在获得监管许可后，计划在六家当地医院的试验中进一步验证canofyMD SCAI。该公司此前透露，其目标是在今年最后一个季度之前推出该应用程序。澳大利亚和新西兰的皮肤癌发病率是世界上最高的国家之一，该公司也正在申请监管部门的批准。。

Furthermore, LifeSemantics will continue conducting clinical trials and pursuing similar regulatory approvals for its other canofyMD solutions, which include mobile software for blood pressure prediction, hypertension complication prediction, and hair density analysis.

此外，LifeSemantics将继续进行临床试验，并为其其他canofyMD解决方案寻求类似的监管批准，其中包括用于血压预测，高血压并发症预测和头发密度分析的移动软件。

WHY IT MATTERS

为什么重要

The number of people getting treated for skin cancers in South Korea has been increasing over the past years. Latest data from the Health Insurance Review and Assessment Service shows that the number of people with skin cancer grew by 34% between 2022 and 2018. Globally, new cases recorded each year top 1.5 million. .

过去几年，韩国接受皮肤癌治疗的人数一直在增加。健康保险审查和评估服务的最新数据显示，2022年至2018年间，皮肤癌患者人数增长了34%。在全球范围内，每年记录的新病例超过150万例。。

Demand for solutions to detect and prevent skin cancers early is driving the growth of the skin cancer diagnosis market, which is expected to be worth $5 billion in 2028 from $3 billion in 2021.

对早期检测和预防皮肤癌的解决方案的需求正在推动皮肤癌诊断市场的增长，预计2028年的价值将从2021年的30亿美元增加到50亿美元。

MARKET SNAPSHOT

市场快照

Early this year in the United States, DermaSensor obtained approval from the Food and Drug Administration for its AI-enabled device for skin cancer detection. It is the first such device intended for primary care which can detect skin cancers with an accuracy high up to 96%.

今年年初，DermaSensor在美国获得了食品和药物管理局的批准，用于检测皮肤癌的人工智能设备。它是第一个用于初级保健的此类设备，可以检测皮肤癌，准确率高达96%。

Australia, which records one of the highest ultraviolet radiation levels and cases of skin cancers worldwide, is also home to innovations in skin cancer diagnosis. ASX-listed Advanced Human Imaging also offers a smartphone-based AI called DermaScan AI for classifying skin conditions based on photos.

澳大利亚是全球紫外线辐射水平和皮肤癌发病率最高的国家之一，也是皮肤癌诊断创新的发源地。ASX上市的Advanced Human Imaging还提供了一种基于智能手机的人工智能DermaScan AI，用于根据照片对皮肤状况进行分类。

It can classify 588 common and rare skin conditions in 133 categories, including all categories of skin cancer..

它可以将588种常见和罕见的皮肤病分为133类，包括所有类别的皮肤癌。。

A team of Australian eye experts are currently trying to adapt a desktop system for measuring UV radiation damage to the eye – a potential early indicator of skin cancer – into smartphones. It will also utilise AI algorithms which they said will work best for mobile software.

澳大利亚眼科专家团队目前正在尝试将一种桌面系统应用于智能手机，该系统用于测量紫外线对眼睛的损伤，这是皮肤癌的潜在早期指标。它还将使用人工智能算法，他们说这些算法最适合移动软件。

AI was also applied to assess and confirm cancerous lesions in images captured in a pop-up clinic project piloted last year. The project by Skin Check Champions, the University of South Australia, and The Hospital Research Foundation was launched during the 2023 Tour Down Under road cycling race.

AI还被用于评估和确认去年试点的弹出式诊所项目中拍摄的图像中的癌性病变。该项目由皮肤检查冠军、南澳大利亚大学和医院研究基金会在2023年公路自行车赛期间启动。

Tags: LifeSemantics, South Korea, canofyMD SCAI, skin cancer, AI, mobile screening, AI diagnosis, mobile health

标签：LifeSemantics，韩国，canofyMD SCAI，皮肤癌，人工智能，移动筛查，人工智能诊断，移动健康

More regional news

Indian ICU tech startup to go global with $11M fundingBy Adam AngJune 27, 2024

印度ICU科技初创公司将以1100万美元的资金走向全球Adam Ang2024年6月27日

Asian gastro docs generally trust and accept AI: surveyBy Adam AngJune 24, 2024

亚洲胃肠病医生普遍信任并接受人工智能：Adam Ang2024年6月24日的调查

South Korea clears stroke AI and more briefsBy Adam AngJune 07, 2024

2024年6月7日，韩国清除中风AI和更多简介